SBRT plus chemoimmunotherapy to save the voice box
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial tests a new approach to treat advanced larynx or hypopharynx cancer without removing the voice box. First, you get targeted radiation (SBRT), then a combination of chemotherapy and an immunotherapy drug called Toripalimab, which helps your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cancer of the voice box (larynx) or the area just below it (hypopharynx) that has spread to nearby tissues or lymph nodes but not to distant parts of the body.
- You are between 18 and 70 years old.
- You are in good enough health to do daily activities (like light housework or office work).
- Your organs (like kidneys, liver, and bone marrow) are working well enough to handle chemotherapy, immunotherapy, and radiation.
- You do not have any other cancers.
- You do not have any medical reasons that would prevent you from receiving immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy before surgery. The goal is to shrink the tumor enough to save the voice box (larynx), instead of removing it. It is for people with advanced throat cancer that can be removed by surgery.
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
This trial tests whether adding a type of radiation therapy (SBRT) to chemoimmunotherapy before surgery helps people with advanced mouth or throat cancer. The goal is to see if this combination can shrink tumors more effectively and improve outcomes.
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
This trial tests combining radiation therapy with immunotherapy and chemotherapy before surgery for advanced oral or throat cancer. The goal is to see if this approach can shrink the tumor and improve treatment outcomes.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemoradiation before surgery helps people with a type of esophageal cancer. It is for patients whose cancer has not spread to other organs and who have not had treatment before.
Hear when a new Laryngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.